source
- Karyopharm stock tumbles after Phase 3 Xpovio trial fails in endometrial cancerKaryopharm announced that its Phase 3 XPORT-EC-042 study of Xpovio in endometrial cancer did not meet its primary endpoint. The failure represents the company's second unsuccessful attempt to expa…
- Early Alert: Percutaneous Catheter Issue from Boston ScientificENROUTE Transcarotid Neuroprotection Systems may have arterial sheath tip separation or partial tip separation during usefda medwatch · 7d ago↗ source